Abstract:
The invention relates to the use of 8,9-dimethyl-5-phenyl-11 H-1 ,3-dioxolo[4,5-h]-imidazo[1 ,2-c][2,3]benzodiazepine: tautomers and N-oxides thereof, as well as pharmacologically acceptable salts, hydrates and solvates of this compound and its tautomers and N-oxides, for the preparation of a pharmaceutical composition for the treatment, amelioration or prevention of dizziness, including vertigo and Meniere's disorder.
Abstract:
The invention concerns sildenafil N-oxide as prodrug, to pharmaceutical compositions containing this compound, to methods for preparing it, and methods for preparing compositions. The invention relates to 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-4-oxido-piperazine having formula (1A) and pharmacologically acceptable salts, hydrates and solvates thereof. The invention also relates to uses of the compound, and compositions containing it, particularly for the manufacture of medicaments useful in the treatment of affections or diseases effectively treatable - albeit with side effects - with sildenafil.
Abstract:
The invention relates to a novel use of known benzazepine, benzoxazepine, benzothiazepine-N-acetic acid and phosphono-substituted benzazepinone derivatives having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity. The compounds of the invention are useful for the preparation of pharmaceutical compositions for prophylaxis and treatment of neurodegenerative disorders. The compounds of the invention are known from the European patents EP 0 733 642 and EP 0 916 679, and can be described by the general formula (1) wherein the symbols have the meanings as given above in the description.
Abstract:
The invention relates to a novel use of known benzazepine, benzoxazepine, benzothiazepine-N-acetic acid and phosphono-substituted benzazepinone derivatives having neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity. The compounds of the invention are useful for the preparation of pharmaceutical compositions for prophylaxis and treatment of neurodegenerative disorders. The compounds of the invention are known from the European patents EP 0 733 642 and EP 0 916 679, and can be described by the general formula (1) wherein the symbols have the meanings as given above in the description.
Abstract:
Uso de un compuesto de fórmula general (1) (Ver fórmula) donde R1 representa un grupo de fórmula (2) o (3): (Ver fórmulas) A representa CH2, O ó S, R2 y R3 representan independientemente hidrógeno o halógeno, R4 y R6 representan independientemente hidrógeno o un grupo que forma un éster carboxílico biolábil; R5 se selecciona del grupo que consiste en alcoxi(C1-C6)alquilo(C1-C6) que puede estar substituído por alcoxi(C1-C6), fenil-alquilo(C1-C6) y feniloxi-alquilo(C1-C6) donde el grupo fenilo puede estar substituído con alquilo(C1-C6), alcoxi(C1-C6) o halógeno, y naftil-alquilo(C1-C6), R7 y R8 representan independientemente hidrógeno o un grupo que forma un éster de ácido fosfónico biolábil, todos los estereoisómeros, así como sales farmacológicamente aceptables de los mismos, para la preparación de composiciones farmacéuticas para la profilaxis y el tratamiento de afecciones seleccionadas del grupo que consiste en lesión cerebral traumática, encefalomielitis aguda diseminada, lesión cerebral relacionada con epilepsia, lesión de la médula espinal, meningitis y meningoencefalitis bacteriana o viral, enfermedades priónicas, envenenamientos con compuestos neurotóxicos, lesión cerebral inducida por radiación y para la profilaxis de íctus isquémico, con la condición de que tales composiciones farmacéuticas no contengan un antagonista del receptor de aldosterona.
Abstract:
La presente se refiere a N-oxido de sildenafil como prodroga, a composiciones farmacéuticas que contienen este compuesto, a métodos para prepararlo, y a métodos para preparar composiciones. Se refiere a 1-[[3-(6,7-dihidro-1-metil-7-oxo-3-propil-1H-pirazolo[4,3-d]pirimidin-5-il)-4-etoxifenil]sulfonil]-4-metil-4-oxido-piperazina que tiene la formula (1) y sales, hidratos y solvatos farmacologicamente aceptables del mismo. También se refiere a usos del compuesto, y composiciones que lo contienen, particularmente para la fabricacion de medicamentos utiles en el tratamiento de disfuncion eréctil o hipertension arterial.